Medication Non-Adherence

0
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
1 program
Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented PatientsN/A1 trial
Active Trials
NCT00998127Completed5,031Est. Mar 2013
Bristol Myers Squibb
1 program
Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented PatientsN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiPatterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients

Clinical Trials (1)

Total enrollment: 5,031 patients across 1 trials

NCT00998127SanofiPatterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients

Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients

Start: Jun 2009Est. completion: Mar 20135,031 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space